How Rare Disease Advocates Can Demonstrate Partnership ROI to Funders and Hospital Systems
Published: 22 Apr 2026
You’ve done the work. Your organization has built relationships, run programs, and created real value for the rare disease community you serve. You know the impact is real because you see it in the patients and families you work with every day.
But when you sit across the table from a hospital system executive, a biotech program director, or a foundation program officer and they ask you to demonstrate the return on their investment in partnering with you — do you have the answer?
For many rare disease advocacy organizations, this is where the conversation stalls. The impact is real. The documentation is not.
This guide is a practical resource for rare disease advocates who want to develop the language, the metrics, and the frameworks to demonstrate partnership ROI in terms that matter to funders and healthcare institutions.
Why Demonstrating Partnership ROI Matters
The rare disease space is competitive for funding. Biotech companies have limited community engagement budgets and many potential partners. Hospital systems have constrained resources and multiple community health priorities. Foundations receive far more applications than they can fund.
Advocacy organizations that can demonstrate the value of partnering with them — in specific, quantifiable terms — are significantly more likely to attract and retain partners than those that rely on mission alignment alone.
This is not about abandoning values for metrics. It is about learning to speak the language of the institutions you need as partners — and developing the evidence that makes your organization’s value undeniable.
Understanding What Different Partners Actually Measure
Before you can demonstrate ROI to a partner, you need to understand what ROI means to them specifically.
Hospital systems typically care about: patient outcomes (readmission rates, quality metrics), community health indicators, regulatory and accreditation requirements related to community benefit, and staff efficiency. A partnership that improves care coordination for sickle cell patients and reduces emergency department visits is demonstrating ROI in terms a hospital system understands.
Biotech and pharmaceutical companies typically care about: clinical trial enrollment and retention, patient community trust, regulatory engagement support, real-world evidence, and CSR goals. A partnership that reduces recruitment timelines or improves diversity in a trial population has clear, quantifiable ROI.
Foundations and government funders typically care about: program reach, populations served, outcomes relative to investment, and evidence of organizational sustainability. A partnership that reaches more patients per dollar invested, with documented outcomes, is a compelling case.
Individual major donors typically care about: personal connection to mission, community impact stories, and evidence that their money is being used effectively. For these donors, a combination of personal narrative and documented outcomes is most persuasive.
The Evidence You Need to Build
Demographic data about your community
How many patients and families do you serve? In what geographies? With what characteristics relevant to your disease area? This is the foundation of your partnership value proposition.
Program outcome data
What changed as a result of your programs? Not activities — outcomes. Patient knowledge, care-seeking behavior, clinical trial enrollment, quality of life measures, peer support connections. Track these systematically, not retrospectively.
Partnership-specific outcomes
For every existing partnership, document what you contributed and what resulted. Number of patients connected to clinical information, number of trial participants recruited, events co-hosted, community members reached. Build this documentation habit into every partnership from day one.
Cost comparisons
How much would it cost a biotech company or hospital system to achieve the same community reach or trust through other means? If recruiting one patient advocate organization generates the equivalent reach and credibility of months of direct community outreach, that is a compelling cost comparison.
Testimonials and case stories
Quantitative data gets attention. Patient and family stories close the deal. Collect both, with consent, consistently.
Framing Partnership ROI for Different Audiences
For hospital systems
“Our organization serves [X] patients and families living with [disease] in [geography]. Last year, [Y] of these patients had unplanned emergency department visits. Through our care coordination partnership model, we have demonstrated a [Z]% reduction in avoidable ED visits among patients engaged with our programs — representing approximately [$] in avoided healthcare costs for partner hospital systems.”
For biotech companies
“Patient advocacy organizations with structured partnership programs have demonstrated average clinical trial recruitment timelines [X]% shorter than industry-led recruitment alone. Our community of [Y] engaged patients and families, combined with our trust-based outreach approach, provides your clinical operations team with direct access to a population that would otherwise take months and significant budget to reach.”
For foundations
“Our programs reached [X] rare disease patients and families last year with [specific intervention]. Pre/post assessment data shows a [Y]% improvement in [specific health knowledge or behavior outcome]. Our cost per patient served is [],comparedtoanaverageof[], compared to an average of [ ],comparedtoanaverageof[] for comparable programs nationally.”
Building the Habit of Impact Documentation
The organizations that demonstrate partnership ROI best are not the ones with the largest budgets or the most staff. They are the ones that built documentation habits from the beginning and maintained them consistently.
Practical steps to start now:
- Define two to three outcome metrics for every program or partnership before it begins
- Collect baseline data before the intervention starts
- Build follow-up data collection into the program design, not as an afterthought
- Assign someone specific to documentation — it won’t happen if it belongs to everyone
- Use your partnership debrief as a documentation moment: what did we accomplish, what evidence do we have?
Frequently Asked Questions
Partnership ROI in rare disease advocacy refers to the measurable value that an advocacy organization provides to its partners — hospital systems, biotech companies, and funders — relative to the investment those partners make. This value can include patient recruitment, community trust, health education outcomes, clinical coordination, and policy influence, among others.
Community trust is most effectively quantified through its outcomes: clinical trial enrollment rates, patient retention in trials, community willingness to engage with research, and the cost comparison between trust-based advocacy recruitment and direct industry outreach. Organizations that can show that their community relationships produce measurable differences in these outcomes are demonstrating the economic value of trust.
The most useful data includes: community size and demographics, program reach and outcomes, partnership-specific contributions (recruitment, referrals, events, education), cost per patient served, and pre/post measurements of relevant health knowledge or behavior outcomes.
Hospital systems typically measure community partnership value through community benefit reporting (a regulatory requirement for nonprofit hospitals), patient outcome metrics, and operational efficiency measures such as reduced emergency department utilization. Advocacy organizations that can contribute evidence relevant to these measures are most compelling to hospital system partners.
Related but not identical. SROI (Social Return on Investment) is a specific methodology for quantifying social outcomes in financial terms, typically used for reporting to funders and stakeholders. Partnership ROI is a broader term for the value an organization provides to its specific partners. SROI analysis can be one component of demonstrating partnership ROI.
Elevate Impact’s platform includes Impact templates for tracking partnership outcomes, the Cross-Collaborative Toolkit’s Measurement and Impact module with SROI frameworks and templates, and community resources on impact documentation and reporting. We also connect members with advisors who specialize in impact measurement and funder communication.
The rare disease advocacy organizations that attract and retain the strongest partners are not necessarily the largest or the best-funded. They are the ones that have learned to speak the language of their partners — demonstrating value in terms that matter to hospital executives, biotech program directors, and foundation officers.
This requires documentation, discipline, and the willingness to measure what matters — not just what is easy to count.
Elevate Impact is here to support this work — with the tools, frameworks, and community to help rare disease advocacy organizations demonstrate their value and build the partnerships they deserve.
